# A repurposing label pathway with short exclusivity that non-profits can hold

Source: https://onco.cc/ideas/idea-fund-repurposing-indication-exclusivity/  
OnCo record `idea-fund-repurposing-indication-exclusivity` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Create a way for a charity or university to get a cheap old drug officially approved for a new cancer use, with a few years of protection on that use so trial costs can be recovered without high prices.

## Summary

A dedicated regulatory pathway for new oncology indications of off-patent drugs, accessible to non-commercial sponsors, with three to five years of indication-specific data exclusivity that can be assigned to a non-profit or public body. The exclusivity is for reimbursement of the indication rather than for the molecule, so generic supply for existing uses is unaffected; a modest per-indication payment from payers repays the trial. Without this, academic repurposing results cannot reach the label and remain off-label and unevenly used.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A repurposing pathway with assignable indication exclusivity increases label changes for off-patent drugs in oncology from near zero to several per year within five years and raises guideline adoption of positive academic repurposing trials.
- Rationale: The EU's STAMP working group and the Belgian and Dutch repurposing frameworks have identified the missing label pathway as the key barrier; the orphan-drug precedent shows that indication-level exclusivity can be designed. The Anticancer Fund's and Cures Within Reach's pipelines provide immediate candidates.
- Proposed test: Legislate a pilot pathway in one region and run two repurposing labels through it, measuring time to label, payer uptake and price.
- Maturity: speculative
- Actor: regulator

## Sources

- Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022): https://doi.org/10.1038/d41573-022-00030-4

## Connected records

- ideas: [A non-profit pharmaceutical company for the cancers markets ignore](https://onco.cc/ideas/idea-fund-nonprofit-pharma/), [Automatic offer of shelved cancer assets to non-profits after two years](https://onco.cc/ideas/idea-fund-shelved-asset-escrow/), [Patent-free open-source development of repurposed and off-patent cancer drugs](https://onco.cc/ideas/idea-fund-open-source-repurposing-leads/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [No incentive to repurpose cheap drugs](https://onco.cc/bottlenecks/b-generic-repurposing/)
- key papers: [Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape](https://onco.cc/key-papers/paper-upadhaya-nat-rev-drug-discov/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-repurposing-indication-exclusivity.json